From: Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis
Clinical and laboratory data | Patients n = 41 | Healthy controls n = 22 | p value |
---|---|---|---|
Women/men (% women) | 32/9 (78%) | 17/5 (77%) | 0.9 |
Agea (years) | 31 (24–36) | 32 (26–41) | 0.3 |
Diagnosis (CIS/RRMS) | 19/22 | N/A | |
Relapse within last 2 months (yes/no) | 23/18 | N/A | |
Mean disease durationb (months) | 11.8 | N/A | |
Median disease durationb (months) | 3.5 | N/A | |
Disease durationb (number of subjects) | N/A | ||
0–1 months | 10 | ||
1.25–2 months | 7 | ||
2.25–3 months | 3 | ||
3.25–6 months | 6 | ||
6.5–12 months | 7 | ||
13–24 months | 3 | ||
25–36 months | 2 | ||
37–48 months | 1 | ||
49–120 months | 2 | ||
Median EDSS | 2.0 | N/A | |
EDSS (number of subjects) | |||
0 | 6 | 22 | |
1.0 | 12 | ||
1.5 | 2 | ||
2.0 | 12 | ||
2.5 | 3 | ||
3.0 | 1 | ||
3.5 | 2 | ||
4.0 | 2 | ||
4.5 | 1 | ||
CSF mononuclear cell counta | 4.6 × 106/L (1.8–9.2) | 2.1 × 106/L (0.9–2.7) | 0.001 |
Albumin ratioa | 4.8 (3.4–6.0) | 4.7 (3.6–5.3) | 0.5 |
IgG indexa | 0.7 (0.5–1.1) | 0.5 (0.5–0.5) | < 0.001 |
IgG synthesis indexa | 1.3 (1.0–2.1) | 0.9 (0.9–1.0) | < 0.001 |
Oligoclonal CSF IgG bands (pos/neg) | 33/8 | 0/22 | < 0.001 |